The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., Oct. 3, 12:55 PM

Slide #12. IDEAYA Biosciences, Inc. Secondary Offering

Company: IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
Date announced: 9/14/2022
Shares Offered: 7,619,048
Date of Pricing: 9/14/2022
Price Per Share: $10.50
Secondary Offering Details: IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $80.0 million of shares of its common stock in an underwritten public offering. In addition, IDEAYA intends to grant the underwriters a 30-day option to purchase up to $12.0 million of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 9/14- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of 7,619,048 shares of its common stock at a public offering price of $10.50 per share, before underwriting discounts and commissions. In addition, IDEAYA has granted the underwriters a 30-day option to purchase up to an additional 1,142,857 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by IDEAYA, are expected to be approximately $80.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about September 19, 2022, subject to the satisfaction of customary closing conditions.

IDEAYA Biosciences is a synthetic lethality-focused precision medicine oncology company engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Co.'s primary synthetic lethality product candidate is IDE397, a clinical-stage methionine adenosyltransferase 2a inhibitor for patients with solid tumors having methylthioadenosine phosphorylase deletions. Co. is enrolling patients into a Phase 1 clinical trial designated as IDE397-001 to evaluate IDE397. Co. is targeting poly (ADP-ribose) glycohydrolase for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures.

IDYA SEC Filing Email Alerts Service

Open the IDYA Page at The Online Investor »

Company Name:  IDEAYA Biosciences Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding IDYA:  21
Total Market Value Held by ETFs:  $62.38M
Total Market Capitalization:  $555.00M
% of Market Cap. Held by ETFs:  11.24%

Open the IDYA Page at The Online Investor (in a new window) »

October 3, 2022    12:55 PM Eastern
Quotes delayed 20 minutes

Email EnvelopeFree IDYA Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.71 out of 4)
62nd percentile
(ranked higher than approx. 62% of all stocks covered)

Analysts' Target Price:
IDYA Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2022, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.